Description
BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX; IC
50 = 8 nM) that targets Cys
496 in the BMX ATP binding domain. It additionally targets the related Bruton’s tyrosine kinase (BTK) with an IC
50 value of 10.4 nM, but is more than 47-656-fold less potent for inhibition of Blk, JAK3, EGFR, Itk, or Tec activity. BMX-IN-1 was shown to inhibit the proliferation of Tel-BMX-transformed Ba/F3 prostate cancer cells with a GI
50 value of 25 nM. Antiproliferative activity was also observed in RV-1, DU-145, PC-3, and VCAP prostate cancer cell lines (GI
50s = 2.54, 4.38, 5.37, and 2.46 μM, respectively).